EP1089995A1 - Paroxetine ascorbate - Google Patents

Paroxetine ascorbate

Info

Publication number
EP1089995A1
EP1089995A1 EP99918151A EP99918151A EP1089995A1 EP 1089995 A1 EP1089995 A1 EP 1089995A1 EP 99918151 A EP99918151 A EP 99918151A EP 99918151 A EP99918151 A EP 99918151A EP 1089995 A1 EP1089995 A1 EP 1089995A1
Authority
EP
European Patent Office
Prior art keywords
paroxetine
ascorbate
paroxetine ascorbate
salt
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99918151A
Other languages
German (de)
French (fr)
Inventor
Michael Smithkline Beecham Pharma. Urquhart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP1089995A1 publication Critical patent/EP1089995A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the present invention relates to a novel compound, to processes for preparing it and to its use in treating medical disorders.
  • paroxetine ascorbate According to the present invention there is provided paroxetine ascorbate.
  • novel salt of this invention is provided in non-crystalline form, which may a solid or an oil.
  • the oil is preferably absorbed on a solid carrier, especially a carrier that is usable as a component of a pharmaceutical composition
  • novel salt of this invention is provided in crystalline form.
  • each polymorph forms another aspect of this invention.
  • Paroxetine ascorbate may be prepared by contacting stoichiometric amounts of ascorbic acid and paroxetine free base.
  • the acid or base is in solution, more preferably both are in solution. Elevated temperature may be used to bring the acid into solution, but good yields of the salt are obtained by evaporation of some or all of the solvent or by controlled cooling, preferably in stages.
  • Most commonly used solvents are suitable for mobilizing paroxetine free base, for example toluene, alcohols such as
  • Suitable solvents for ascorbic acid include water and lower alcohols.
  • the salt may be isolated in solid form by conventional means from a solution thereof obtained as above.
  • the non-crystalline salt may be prepared by precipitation, spray drying, and freeze drying of solutions, or vacuum drying of oils, or solidification of melts obtained from reaction of the free base and the acid.
  • the crystalline salt may be prepared by crystallization or recrystallization from appropriate solvents.
  • Solvates may be returned to the unsolvated salt by heating, for example by oven-drying, or by treatment with a displacement solvent which does not form a solvate.
  • water Prior to the isolation of the paroxetine salt, water may be removed by azeotropic distillation to avoid the formation of hydrates or to obtain the product in anhydrous form.
  • suitable solvents for the solution of the salt are those which form an azeotrope with water such as toluene and propan-2-ol. It should also be appreciated that mixtures of solvents can also be used to aid the azeotropic removal of water.
  • crystallization may be carried out from any solvent which allows formation of the desired crystal structure, using seeds of the desired structure where necessary or desirable.
  • individual polymo ⁇ hs are preferably crystallized directly from a solution of the salt, although recrystallizing a solution of one polymo ⁇ h using seeds of another polymo ⁇ h may also be carried out.
  • Paroxetine free base may be prepared according to the procedures generally outlined in US Patent No 4,007,196 and EP-B-0 223403. Ascorbic acid is commercially available.
  • the compounds of this invention may be used to treat and prevent the following disorders:
  • the Disorders are herein after referred to as "the Disorders”.
  • the present invention further provides a method for treating and/or preventing any one or more of the Disorders by administering an effective and/or prophylactic amount of a salt of the invention to a sufferer in need thereof.
  • the present invention further provides a pharmaceutical composition for use in the treatment and/or prevention of the Disorders which comprises an admixture of a salt of the invention with a pharmaceutically acceptable carrier.
  • the present invention also provides the use of a salt of the invention for treating and/or preventing the Disorders.
  • the present invention also provides the use of a salt of the invention in the manufacture of a medicament for treating and/or preventing the Disorders.
  • the present invention is applied to the treatment of depression, OCD and panic.
  • compositions of this invention are usually adapted for oral administration, but formulations for dissolution for parental administration are also within the scope of this invention.
  • the composition is usually presented as a unit dose composition containing from 1 to 200mg of active ingredient calculated on a free base basis, more usually from 5 to lOOmg, for example 10 to 50mg such as 10, 12.5, 15, 20, 25, 30 or 40mg by a human patient. Most preferably unit doses contain 20mg of active ingredient calculated on a free base basis. Such a composition is normally taken from 1 to 6 times daily, for example 2, 3 or 4 times daily so that the total amount of active agent administered is within the range 5 to 400mg of active ingredient calculated on a free base basis. Most preferably the unit dose is taken once a day.
  • Preferred unit dosage forms include tablets or capsules.
  • compositions of this invention may be formulated by conventional methods of admixture such as blending, filling and compressing.
  • Suitable carriers for use in this invention include a diluent, a binder, a disintegrant, a colouring agent, a flavouring agent and/or preservative. These agents may be utilized in conventional manner, for example in a manner similar to that already used for marketed anti-depressant agents.
  • compositions include those described EP-B-0- 223403, and US 4,007,196 in which the products of the present invention may be used as the active ingredients.
  • Example 1 Preparation of paroxetine ascorbate
  • the tablets are made satisfactorily on a single punch or a Rotary press.
  • Dihydrate are screened and mixed together in a suitable mixer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Paroxetine ascorbate is useful in the treatment of certain CNS disorders.

Description

PAROXETINE ASCORBATE
The present invention relates to a novel compound, to processes for preparing it and to its use in treating medical disorders.
Pharmaceutical products with antidepressant and anti-Parkinson properties are described in US-A-3912743 and US-A-4007196. An especially important compound among those disclosed is paroxetine, the (-)trαrø isomer of 4-(4'-fluorophenyl)-3-(3',4'-methylenedioxy- phenoxymethyl)-piperidine. This compound is used in therapy as the hydrochloride salt for the treatment and prophylaxis of inter alia depression, obsessive compulsive disorder (OCD) and panic.
We have now surprisingly discovered a novel salt of paroxetine which may be used as an alternative to the currently marketed hydrochloride, or as an intermediate in the preparation of the hydrochloride .
According to the present invention there is provided paroxetine ascorbate.
In one aspect the novel salt of this invention is provided in non-crystalline form, which may a solid or an oil. The oil is preferably absorbed on a solid carrier, especially a carrier that is usable as a component of a pharmaceutical composition
In another aspect the novel salt of this invention is provided in crystalline form. When the crystalline form exists as more than one polymorph, each polymorph forms another aspect of this invention.
Paroxetine ascorbate may be prepared by contacting stoichiometric amounts of ascorbic acid and paroxetine free base. Preferably either the acid or base is in solution, more preferably both are in solution. Elevated temperature may be used to bring the acid into solution, but good yields of the salt are obtained by evaporation of some or all of the solvent or by controlled cooling, preferably in stages. Most commonly used solvents are suitable for mobilizing paroxetine free base, for example toluene, alcohols such as
-1- methanol, ethanol, propan-2-ol, esters such as ethyl acetate, ketones such as acetone and butanone, halogenated hydrocarbons such as dichloromethane, and ethers such as tetrahydrofuran and diethyl ether, but solvents in which ascorbic acid is very insoluble are preferably avoided. Suitable solvents for ascorbic acid include water and lower alcohols.
The salt may be isolated in solid form by conventional means from a solution thereof obtained as above. For example, the non-crystalline salt may be prepared by precipitation, spray drying, and freeze drying of solutions, or vacuum drying of oils, or solidification of melts obtained from reaction of the free base and the acid. The crystalline salt may be prepared by crystallization or recrystallization from appropriate solvents.
When the salt is obtained as a solvate, by association with the solvent in which it is dissolved, such solvate forms a further aspect of this invention. Solvates may be returned to the unsolvated salt by heating, for example by oven-drying, or by treatment with a displacement solvent which does not form a solvate.
Prior to the isolation of the paroxetine salt, water may be removed by azeotropic distillation to avoid the formation of hydrates or to obtain the product in anhydrous form. In that case, suitable solvents for the solution of the salt are those which form an azeotrope with water such as toluene and propan-2-ol. It should also be appreciated that mixtures of solvents can also be used to aid the azeotropic removal of water.
More generally, crystallization may be carried out from any solvent which allows formation of the desired crystal structure, using seeds of the desired structure where necessary or desirable. When polymoφhs exist, individual polymoφhs are preferably crystallized directly from a solution of the salt, although recrystallizing a solution of one polymoφh using seeds of another polymoφh may also be carried out.
Paroxetine free base may be prepared according to the procedures generally outlined in US Patent No 4,007,196 and EP-B-0 223403. Ascorbic acid is commercially available.
The compounds of this invention may be used to treat and prevent the following disorders:
-2- Alcoholism Anxiety
Depression Obsessive Compulsive Disorder
Panic Disorder Chronic Pain
Obesity Senile Dementia
Migraine Bulimia
Anorexia Social Phobia
Pre-Menstrual Syndrome (PMS) Adolescent Depression
Trichotillomania Dysthymia
Substance Abuse
These disorders are herein after referred to as "the Disorders".
The present invention further provides a method for treating and/or preventing any one or more of the Disorders by administering an effective and/or prophylactic amount of a salt of the invention to a sufferer in need thereof.
The present invention further provides a pharmaceutical composition for use in the treatment and/or prevention of the Disorders which comprises an admixture of a salt of the invention with a pharmaceutically acceptable carrier.
The present invention also provides the use of a salt of the invention for treating and/or preventing the Disorders.
The present invention also provides the use of a salt of the invention in the manufacture of a medicament for treating and/or preventing the Disorders.
Most suitably the present invention is applied to the treatment of depression, OCD and panic.
The compositions of this invention are usually adapted for oral administration, but formulations for dissolution for parental administration are also within the scope of this invention.
-3- The composition is usually presented as a unit dose composition containing from 1 to 200mg of active ingredient calculated on a free base basis, more usually from 5 to lOOmg, for example 10 to 50mg such as 10, 12.5, 15, 20, 25, 30 or 40mg by a human patient. Most preferably unit doses contain 20mg of active ingredient calculated on a free base basis. Such a composition is normally taken from 1 to 6 times daily, for example 2, 3 or 4 times daily so that the total amount of active agent administered is within the range 5 to 400mg of active ingredient calculated on a free base basis. Most preferably the unit dose is taken once a day.
Preferred unit dosage forms include tablets or capsules.
The compositions of this invention may be formulated by conventional methods of admixture such as blending, filling and compressing.
Suitable carriers for use in this invention include a diluent, a binder, a disintegrant, a colouring agent, a flavouring agent and/or preservative. These agents may be utilized in conventional manner, for example in a manner similar to that already used for marketed anti-depressant agents.
Specific examples of pharmaceutical compositions include those described EP-B-0- 223403, and US 4,007,196 in which the products of the present invention may be used as the active ingredients.
The following Examples illustrate the present invention: Example 1: Preparation of paroxetine ascorbate
A 1.28 mol solution of paroxetine base in toluene (5 ml, 6.38 mmol) was added to a solution of ascorbic acid (1.12g, 6.38 mmol) in methanol (15 ml). The solvent was removed in vacuo, the residual oil was diluted with toluene (15 ml) and the solvent removed in vacuo. Trituration with diethyl ether (c. 15 ml) and filtration under nitrogen gave a pale yellow solid which was washed with diethyl ether (2 x 10 ml), dried in a vacuum desiccator for 3 hours.
Yield 2.99g.
IR nujol mull:
Bands at 1716, 1603, 1510, 1465, 1377, 1224, 1186, 1136, 1037, 930, 831, 722, 540 cm"1.
Example 2: preparation of tablets
INGREDIENTS 20 mg Tablet 30mg Tablet
Paroxetine ascorbate 20.00 mg 30.0 mg
(based on free base) (based on free base)
Dicalcium Phosphate (DCP) 83.34 mg 125.0 mg
Microcrystalline Cellulose 50.67 mg 76.0 mg
Sodium Starch Glycollate 8.34 mg 12.5 mg
Magnesium Stearate 1.67 mg 2.5 mg
Commercial source of the ingredients
Dicalcium Phosphate Dihydrate Emcompress or Ditab* Microcrystalline Cellulose Avicel PH 102* Sodium Starch Glycollate Explotab.*
* Tradenames
Method
-5- 1. Pass DCP through a screen and weigh it into a Planetary mixer.
2. Add 30 mesh Paroxetine Ascorbate to the bowl.
3. Add 20 mesh Avicel and Explotab and mix all the powders for 10 minutes. 4. Add magnesium stearate and mix for 5 minutes.
Tablet into Pentagonal Tablets using the following punches:
30 mg Tablet 9.5 mm Circumcircle 20 mg Tablet 8.25 mm Circumcircle
The tablets are made satisfactorily on a single punch or a Rotary press.
Example 3: preparation of tablets
INGREDIENTS 10 mg Tablet 20 mg Tablet 30mg Tablet
Paroxetine ascorbate 10 mg 20 mg 30 mg
(as on free base) (as on free base) (as on free base)
Sodium Starch Glycollate 2.98 mg 5.95 mg 8.93 mg
Granular Dicalcium
Phosphate 158.88 mg 317.75 mg 476.63 mg
(DITAB) or Dicafos
Magnesium Stearate 1.75 mg 3.50 mg 5.25 mg
Method
1. Paroxetine ascorbate, Sodium Starch Glycollate and Dicalcium Phosphate
Dihydrate are screened and mixed together in a suitable mixer.
-6- (Planetary, Cuble or High Energy Shear mixer.) 2. Add Magnesium Stearate and compress it into a tablet using a single punch or
Rotary Tablet machine.
-7-

Claims

1. Paroxetine ascorbate.
2. A compound according to claim 1 in non-crystalline form.
3. A compound according to claim 1 in crystalline form.
4. A process for the preparation of a compound as claimed in claim 1 or 2 by precipitation, spray drying or freeze drying a solution of paroxetine ascorbate, or by vacuum drying of oils of paroxetine ascorbate, or solidification of melts of paroxetine ascorbate.
5. A process for the preparation of a compound as claimed in claim 1 or 3 by crystallization or re-crystallization from a solution of paroxetine ascorbate.
6. A process according to claim 4 or 5 in which the solution, oil or melt of paroxetine ascorbate is prepared by treating paroxetine free base with ascorbic acid.
7. A method for treating and/or preventing any one or more of the Disorders by administering an effective and/or prophylactic amount of paroxetine ascorbate to a sufferer in need thereof.
-8-
EP99918151A 1998-04-25 1999-04-23 Paroxetine ascorbate Withdrawn EP1089995A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9808896 1998-04-25
GBGB9808896.6A GB9808896D0 (en) 1998-04-25 1998-04-25 Novel compound
PCT/GB1999/001244 WO1999055698A1 (en) 1998-04-25 1999-04-23 Paroxetine ascorbate

Publications (1)

Publication Number Publication Date
EP1089995A1 true EP1089995A1 (en) 2001-04-11

Family

ID=10831008

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99918151A Withdrawn EP1089995A1 (en) 1998-04-25 1999-04-23 Paroxetine ascorbate

Country Status (20)

Country Link
EP (1) EP1089995A1 (en)
JP (1) JP2002513019A (en)
KR (1) KR20010042977A (en)
CN (1) CN1297448A (en)
AP (1) AP2000001963A0 (en)
AU (1) AU3618499A (en)
BG (1) BG104940A (en)
BR (1) BR9909868A (en)
CA (1) CA2330055A1 (en)
EA (1) EA200001104A1 (en)
GB (1) GB9808896D0 (en)
HU (1) HUP0102116A3 (en)
ID (2) ID26654A (en)
IL (1) IL139081A0 (en)
NO (1) NO20005352L (en)
PL (1) PL343677A1 (en)
SK (1) SK15912000A3 (en)
TR (1) TR200003084T2 (en)
WO (1) WO1999055698A1 (en)
ZA (1) ZA200005912B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
IL159280A0 (en) * 2001-06-14 2004-06-01 Teva Pharma A process for preparing paroxetine hcl which limits formation of pink colored compounds
JP4508646B2 (en) * 2002-01-09 2010-07-21 エミスフェアー・テクノロジーズ・インク Polymorph of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate
CN110607554B (en) * 2018-10-30 2024-03-22 中国科学院化学研究所 Method for preparing medicine or medicine intermediate monocrystal or amorphous substance

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
ES2117557B1 (en) * 1996-02-29 1999-07-01 Ferrer Int NEW PROCEDURE FOR OBTAINING (-) - TRANS -N-P-FLUOROBENZOILMETIL-4- (P-FLUOROFENIL) -3- ((3,4- (METHYLENDIOXI) PHENOXI) METHYL) -PIPERIDINE.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9955698A1 *

Also Published As

Publication number Publication date
PL343677A1 (en) 2001-08-27
BR9909868A (en) 2000-12-19
NO20005352D0 (en) 2000-10-24
JP2002513019A (en) 2002-05-08
SK15912000A3 (en) 2001-04-09
TR200003084T2 (en) 2001-02-21
AP2000001963A0 (en) 2000-12-31
CN1297448A (en) 2001-05-30
ZA200005912B (en) 2001-12-19
NO20005352L (en) 2000-10-24
WO1999055698A1 (en) 1999-11-04
ID26654A (en) 2001-01-25
HUP0102116A2 (en) 2002-05-29
KR20010042977A (en) 2001-05-25
AU3618499A (en) 1999-11-16
HUP0102116A3 (en) 2002-12-28
IL139081A0 (en) 2001-11-25
BG104940A (en) 2001-09-28
GB9808896D0 (en) 1998-06-24
EA200001104A1 (en) 2001-04-23
ID26083A (en) 2000-11-23
CA2330055A1 (en) 1999-11-04

Similar Documents

Publication Publication Date Title
US20040242506A1 (en) Paroxetine glycyrrhizinate
EP1053234A1 (en) Salts of paroxetine
WO2000035873A1 (en) Process for preparation of paroxetine maleate
EP1089995A1 (en) Paroxetine ascorbate
CA2327450A1 (en) Paroxetine maleate
EP1076659A1 (en) Paroxetine 10-camphorsulfonate for treatment of cns disorders
MXPA00010439A (en) Paroxetine ascorbate
US20030028027A1 (en) Paroxetine maleate
MXPA00010435A (en) Paroxetine 10-camphorsulfonate for treatment of cns disorders
CZ20003942A3 (en) Paroxetine ascorbate
AU2528899A (en) Salts of paroxetine
WO2001014369A2 (en) Process for the preparation of paroxetin.hcl
WO2001025230A1 (en) Process for the preparation of paroxetine hydrochloride acetone solvate
EP1408039A2 (en) Mixed paraxetine propan-2-ol solvates
CZ20003941A3 (en) Paroxetine 10-camphorsulfonate for treating disorders of central neural system
MXPA00009884A (en) Paroxetine maleate
CZ20003722A3 (en) Paroxetine maleate
MXPA00007719A (en) Salts of paroxetine
WO2001025201A1 (en) Process for the preparation of paroxetin intermediate
WO2001025232A1 (en) Process for the preparation of paroxetine hydrochloride acetone solvate
WO2000032596A1 (en) Amine salts of paroxetine
WO2001025231A1 (en) Process for the preparation of paroxetine hydrochloride acetone solvate

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001025

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: RO PAYMENT 20001025;SI PAYMENT 20001025

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021103

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1037876

Country of ref document: HK